Mani (7730) Fundamentals 2026 — P/E 22.7x, Revenue Analysis | SniperIQ
Mani (7730) is a JP-listed Healthcare company in Medical - Specialties with a market capitalization of ¥153.7B, trading at ¥1560.00 on the JPX. This SniperIQ fundamentals page covers Mani's valuation (P/E 22.7x, P/B 2.7x), profitability (net margin 21.1%), revenue (¥30.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mani's market cap?
Mani (7730) has a market capitalization of approximately ¥153.7B, trading at ¥1560.00 on the JPX. Market cap moves with the live share price.
What is Mani's P/E ratio?
Mani's trailing twelve-month P/E ratio is 22.7x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mani?
Mani runs a net profit margin of 21.1%, a gross margin of 66.3%, and an operating margin of 29.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mani generate?
Mani reported revenue of ¥30.0B for fiscal year 2025, with net income of ¥4.6B and earnings per share (EPS) of 47.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mani pay a dividend?
Mani offers a trailing dividend yield of about 2.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Mani financially healthy?
Mani carries a debt-to-equity ratio of 0.00x and a current ratio of 8.04x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mani a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mani (7730) the key facts are: market cap ¥153.7B, P/E 22.7x, revenue ¥30.0B, 52-week range 1236.5-1955. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mani's full fundamentals live
Get Mani's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.